

Press Release

ProStrakan Group plc

Update on US Regulatory Progress of FORTESTA

Galashiels, UK. 1st July 2010 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that on 30th June 2010 Endo Pharmaceuticals Inc. (NASDAQ: ENDP), its US partner for FORTESTA™ (testosterone) 2% Gel, submitted a Complete Response to the US Food and Drug Administration's (FDA) letter of October 2009 related to the New Drug Application submission for FORTESTA.

This Class 2 re-submission is the next step in Endo's intention to offer FORTESTA as a new treatment option in the US for men diagnosed with low testosterone, also known as hypogonadism. The principal content of the re-submission is a re-analysis of the primary variable (testosterone levels) in the original pivotal study. This re-analysis has confirmed the reliability of the original conclusions of the study. In addition, Endo has provided information in the Complete Response about its plans for a post-approval "hand-wash" study. The FDA's review period for Class 2 re-submissions typically is six months.

FORTESTA is a patented 2% testosterone transdermal gel which utilises a metered dose delivery system designed to permit accurate dose adjustment to individual patient requirements. This product is currently approved in the EU and marketed by ProStrakan in a number of European countries under the brand names: Tostran, Tostrex, Fortigel and Itnogen. In August 2009, ProStrakan signed an exclusive licensing and distribution for FORTESTA in the US with Endo.

Dr Wilson Totten, Chief Executive of ProStrakan, said:

“We are confident that, with the re-analysis confirming the reliability of the results of the pivotal study included in the original ProStrakan submission, FORTESTA can be approved by the FDA, making it available as a treatment option for the testosterone replacement therapy market in the US.”

Ends

Further enquiries:

ProStrakan

Dr Wilson Totten, Chief Executive
Allan Watson, Chief Financial Officer
Callum Spreng, Corporate Comms

Tel: +44 (0) 1896 664000

Brunswick Group

Jon Coles / Justine McIlroy

Tel: +44 (0) 20 7404 5959

About Hypogonadism

Male hypogonadism is frequently characterised by reduced libido, loss of muscle mass, bone density and diminished energy levels. These symptoms can be alleviated through testosterone replacement therapy.

An estimated 13.8 million American men have testosterone levels characterised as below normal (testosterone <300ng/dl). However, only approximately 9% of men with low testosterone are treated with testosterone replacement therapy.

1. Araujo AB, O'Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 2004; 89(12): 5920–5926.

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by its own commercial subsidiaries in the UK, US, France, Germany, Spain and Italy. In addition to direct sales, the company has 36 international partners covering 303 global product alliances.

Further details on the business can be found at: www.prostrakan.com